NEWS
ROCHE ENTERS AGREEMENT TO ACQUIRE LUMIRADX ' S POINT OF CARE TECHNOLOGY
Roche has announced the entry into a definitive agreement to acquire select parts of the LumiraDx group related to LumiraDx ’ s innovative Point of Care technology . Following closing of the transaction , which is expected by mid-2024 , the acquired entities will be fully integrated into Roche Diagnostics .
The transaction is part of Roche ’ s vision to enable more patient-centric healthcare , with Point of Care solutions that span the entire patient journey – from the home , pharmacy and general practitioner ’ s office to the emergency room , intensive care unit and beyond . The acquired technology platform offers a wide range of immunoassay and clinical chemistry tests , with great potential for additional high medical value tests in the future . These are capable of being stored at room temperature which enables convenient handling in a range of decentralised healthcare settings . By leveraging its extensive global reach and established affiliate network , Roche will be able to drive access to timely , accurate diagnostic results when and where patients need them most .
“ The addition of the LumiraDx technology to our diagnostics portfolio will enable us to transform testing at the point of care .” said Matt Sause , CEO Roche Diagnostics . “ LumiraDx has developed a highly versatile platform that delivers strong performance across multiple disease areas and technologies . We believe this will enable better patient access to timely results in decentralised healthcare settings worldwide .” Veronique Ameye , Chief Executive Officer of LumiraDx added : “ We are thrilled that Roche will continue this important work and increase its reach around the globe . This will enable more patients to get fast and easy access to better diagnostic testing .”
DENTAL ROBOTICS LEADER NEOCIS SECURES US $ 20M IN FUNDING the backing of our newest investors , including NVentures and Mirae Asset Financial Group , as well as our existing partners . This funding positions us for continued success in the market and will help us drive meaningful innovation in implant dentistry .”
Neocis , a global leader in robot-assisted dental implant surgery , has announced that the company has raised US $ 20M in additional funding .
Neocis manufactures and markets Yomi , dentistry ’ s first and only robotic surgical system cleared by the US Food and Drug Administration ( FDA ). The Yomi platform , which has received a total of 16 FDA 510 ( k ) clearances , assists clinicians during all phases of implant placement via streamlined digital planning and haptic guidance of surgical instrumentation , so users can deliver precise and efficient treatment . To date , more than 40,000 implants have been placed with robotic assistance . A dental implant is placed with Yomi approximately every six minutes , according to current data from Neocis .
“ The latest investment is a testament to our growth as a company and how far dental robotics has come since the first Yomi systems were installed ,” said Alon Mozes , Neocis ’ Co-founder and CEO . “ We ’ re tremendously grateful to have
www . intelligenthealth . tech 11